Gastroretentive drug delivery systems for therapeutic management of peptic ulcer

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 31, Issue 6, 2014, Pages 531-557

  Garg, Tarun ^a   Kumar, Animesh ^a   Rath, Goutam ^a   Goyal, Amit K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Bioadhesive System; Expandable system; Floating system; Gastroretention; Magnetic system

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM MAGNESIUM HYDROXIDE; AMOXICILLIN; BISMUTH CITRATE; BISMUTH SALICYLATE; CALCIUM CARBONATE; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE; HYDROCHLORIC ACID; LANSOPRAZOLE; LEUKOTRIENE C4; LEUKOTRIENE D4; MAGNESIUM CARBONATE; MAGNESIUM HYDROXIDE; MAGNESIUM TRISILICATE; METRONIDAZOLE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROSTAGLANDIN; RABEPRAZOLE; RANITIDINE; SUCRALFATE; TETRACYCLINE; THROMBOXANE A2; UNINDEXED DRUG;

ARTICLE; BIOADHESIVE DRUG DELIVERY SYSTEM; CONTROLLED DRUG RELEASE; DIGESTIVE FUNCTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EFFERVESCENT SYSTEM; EXPANDABLE DRUG DELIVERY SYSTEM; FLOATING DRUG DELIVERY SYSTEM; GASTRORETENTION; GASTRORETENTIVE DRUG DELIVERY SYSTEM; HIGH DENSITY DRUG DELIVERY SYSTEM; HUMAN; HYDROGEL; MAGNETIC DRUG DELIVERY SYSTEM; MUCOADHESIVE DRUG DELIVERY SYSTEM; NONEFFERVESCENT SYSTEM; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; RAFT FORMING SYSTEM; SMOKING; STOMACH EMPTYING; STOMACH SURGERY; SWELLABLE DRUG DELIVERY SYSTEM; SYMPTOM; THEORY; BIOAVAILABILITY; DRUG EFFECTS; METABOLISM; STOMACH;

BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; PEPTIC ULCER; STOMACH;

EID: 84907288023     PISSN: 07434863     EISSN: 2162660X     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.2014011104     Document Type: Article

References (120)

1. Matsuhashi N. [Peptic ulcer (gastro-duodenal ulcer, acute gastric mucosal lesion, NSAIDs-induced ulcer)]. Nihon Rinsho. 2012;70 Suppl 6:553–6.
2. Lu LS, Lin SC, Kuo CM, Tai WC, Tseng PL, Chang KC. A real world report on intravenous highdose and non-high-dose proton-pump inhibitors therapy in patients with endoscopically treated high-risk peptic ulcer bleeding. Gastroenterol Res Pract. 2012:858612.
3. Singh JA, Lewallen DG. Peptic ulcer disease and heart disease are associated with periprosthetic fractures after total hip replacement. Acta Orthop. 2012;83(4):353–9.
4. Shiotani A, Kamada T, Haruma K. NSAID-associated peptic ulcer and H. pylori infection. Nihon Shokakibyo Gakkai Zasshi. 2012;109(1):54–9.
5. Haruma K, Kamada T, Shiotani A. Adverse effects of drugs for peptic ulcer diseases. Nihon Rinsho. 2012;70 Suppl 6:266–71.
6. Levin DA, Watermeyer GA, Deetleefs E, Metz DC, Thomson SR. The efficacy of endoscopic therapy in bleeding peptic ulcer patients. S Afr Med J. 2012;102(5):290–3.
7. Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv. 2013. Epub ahead of print. Cited in PubMed; PMID 12000309.
8. Laursen SB. Treatment and prognosis in peptic ulcer bleeding. Dan Med J. 2014;61(1):B4797.
9. de Korwin JD. [Helicobacter pylori 30 years after: What’s new?]. Rev Med Interne. 2014;Sep;35(9):561–4.
10. Garg T, Rath G, Goyal AK. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv. 2014. Epub ahead of print. Cited in PubMed; PMID 24456019.
11. Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS, Chan FK. Challenges in the management of acute peptic ulcer bleeding. Lancet. 2013;381(9882):2033–43.
12. Nagano Y, Matsui H, Tamura M, Shimokawa O, Nakamura Y, Kaneko T. NSAIDs and acidic environment induce gastric mucosal cellular mitochondrial dysfunction. Digestion. 2012;85(2): 131–5.
13. Chu KM, Cho CH, Shin VY. Nicotine and gastrointestinal disorders: its role in ulceration and cancer development. Curr Pharm Des. 2013;19(1):5–10.
14. Shiotani A, Kamada T, Kusunoki H, Manabe N, Haruma K. [Proton pump inhibitor H2 receptor antagonist]. Nihon Rinsho. 2011;69(6):1032–8.
15. Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst. 2014;31(1):49–88.
16. Garg T, Goyal AK. Biomaterial-based scaffolds— current status and future directions. Expert Opin Drug Deliv. 2014;11(5):767–89.
17. Fu RG, Wang Y, Yuan HZ, Zhou JP, Wang L, Liu XD. Effects of chronic renal failure on gastrointestinal motility: a study on the changes of gastric emptying, small intestinal transit, interdigestive myoelectric complex, and fecal water content. Ren Fail. 2011;33(6):615–21.
18. Zhang YM, Liu XL, Xue DB, Wei YW, Yun XG. Myoelectric activity and motility of the Roux limb after cut or uncut Roux-en-Y gastrojejunostomy. World J Gastroenterol. 2006;12(47):7699–704.
19. Stolk MF, van Erpecum KJ, Smout AJ, Akkermans LM, Jansen JB, Lamers CB. Motor cycles with phase III in antrum are associated with high motilin levels and prolonged gallbladder emptying. Am J Physiol. 1993;264(4 Pt 1):G596–600.
20. Peiper C, Titkova SM, Polivoda M, Anurov M, Arlt G, Ottinger AP. Electrophysiological and mechanical activity of the upper gastrointestinal tract after duodenoplasty or segmental resection of benign gastric outlet stenosis. Dig Dis Sci. 2000;45(3):529–37.
21. Adhikary A, Vavia PR. Bioadhesive ranitidine hydrochloride for gastroretention with controlled microenvironmental pH. Drug Dev Ind Pharm. 2008;34(8):860–9.
22. El Gamal SS, Naggar VF, Allam AN. Optimization of acyclovir oral tablets based on gastroretention technology: factorial design analysis and physicochemical characterization studies. Drug Dev Ind Pharm. 2011;37(7):855–67.
23. Patil GB, Singh SS, Ramani KP, Chatap VK, Deshmukh PK. Design and development of novel dualcompartment capsule for improved gastroretention. ISRN Pharm. 2013;2013:752471.
24. Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner E, Friedman M. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm. 2004;277(1):141–53.
25. Coupe AJ, Davis S., Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res. 1991;8(3):360–4.
26. Clarke G, Newton J, Short M. Gastrointestinal transit of pellets of differing size and density. Int J Pharm. 1993;100(1):81–92.
27. Shah S, Qaqish R, Patel V, AMIJI M. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J Pharm Pharm. 1999;51(6):667–72.
28. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems. Drug Deliv. 2011;18(2):97–110.
29. Kiss D, Zelko R. [Gastroretentive dosage forms]. Acta Pharm Hung. 2005;75(3):169–76.
30. Klausner EA, Lavy E, Barta M, Cserepes E, Friedman M, Hoffman A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res. 2003;20(9):1466–73.
31. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release. 2003;90(2):143–62.
32. Klausner EA, Lavy E, Stepensky D, Friedman M, Hoffman A. Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm Res. 2002;19(10):1516–23.
33. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release. 2006;111(1-2):1–18.
34. Groning R, Cloer C, Georgarakis M, Muller RS. Compressed collagen sponges as gastroretentive dosage forms: in vitro and in vivo studies. Eur J Pharm Sci. 2007;30(1):1–6.
35. Gurnany E, Manwani R, Singhai P, Jain R, Jain A. Gastro-retentive floating multiparticulate drug delivery system: a review. Curr Drug Deliv. 2012. Epub ahead of print; Cited in PubMed; PMID 22452407.
36. Moes AJ. Gastroretentive dosage forms. Crit Rev Ther Drug Carrier Syst. 1993;10(2):143–95.
37. Nama M, Gonugunta CS, Reddy Veerareddy P. Formulation and evaluation of gastroretentive dosage forms of clarithromycin. AAPS PharmSciTech. 2008;9(1):231–7.
38. Ali JH, S, Ali M. Formulation and development of gastroretentive drug delivery system for ofloxacin. Method Find Exp Clin Pharmacol. 2006;28(7):433–40.
39. Shirsand SB, Suresh S, Jodhana LS, Swamy PV. Formulation design and optimization of fast disintegrating Lorazepam tablets by effervescent method. Indian J Pharm Sci. 2010;72(4):431–6.
40. Garg T, Arora S, Murthy R. Patented microencapsulation techniques and its application. J Pharmacy Res. 2011;4(7):2097–102.
41. Gao Y, Liu H, Yuan J, Yang Y, Che X, Hou Y. Loading and release of amine drugs by ion-exchange fibers: role of amine type. J Pharma Sci. 2014; 103(4):1095–103.
42. Javadzadeh Y, Hamedeyazdan S. Novel Drug Delivery Systems for Modulation of Gastrointestinal Transit Time. In: Sezer, AD, editor. Recent Advances in Drug Carrier Systems. Intechopen.com; 2012. Chapter 14.
43. Rapolu K, Sanka K, Vemula PK, Aatipamula V, Mohd AB, Diwan PV. Optimization and characterization of gastroretentive floating drug delivery system using Box-Behnken design. Drug Dev Indust Pharm. 2013;39(12):1928–35.
44. Asnaashari S, Khoei NS, Zarrintan MH, Adibkia K, Javadzadeh Y. Preparation and evaluation of novel metronidazole sustained release and floating matrix tablets. Pharm Dev Technol. 2011;16(4): 400–7.
45. Zhu X, Qi X, Wu Z, Zhang Z, Xing J, Li X. Preparation of multiple-unit floating-bioadhesive cooperative minitablets for improving the oral bioavailability of famotidine in rats. Drug Deliv. 2014(0): 1–8.
46. El-Zahaby SA, Kassem AA, El-Kamel AH. Design and evaluation of gastroretentive levofloxacin floating mini-tablets-in-capsule system for eradication of Helicobacter pylori. Saudi Pharma J. 2014.
47. Garg T, Goyal AK. Iontophoresis: drug delivery system by applying an electrical potential across the skin. Drug Deliv Lett. 2012;2(4):270–80.
48. Getyala A, Gangadharappa HV, Prasad MS, Reddy MP, Kumar TM. Formulation and evaluation of non-effervescent floating tablets of losartan potassium. Curr Drug Deliv. 2013;10(5):620–9.
49. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters on drug release. Euro J Pharm Sci. 2003;18(1):37–45.
50. Awasthi R, Kulkarni GT, Pawar VK, Garg G. Optimization studies on gastroretentive floating system using response surface methodology. AAPS PharmSciTech. 2012;13(1):85–93.
51. Jain A, Pandey V, Ganeshpurkar A, Dubey N, Bansal D. Formulation and characterization of floating microballoons of nizatidine for effective treatment of gastric ulcers in murine model. Drug Deliv. 2014(0):1–6.
52. Jiang H, Tian R, Hu W, Jia Y, Yuan P, Wang J. Formulation and evaluation of gastroretentive floating drug delivery system of dipyridamole. Drug Dev Indust Pharm. 2014(0):1–7.
53. Rajput P, Singh D, Pathak K. Bifunctional capsular dosage form: novel fanicular cylindrical gastroretentive system of clarithromycin and immediate release granules of ranitidine HCl for simultaneous delivery. Int J Pharm. 2014;461(1):310–21.
54. Yang L, Eshraghi J, Fassihi R. A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation. J Control Release. 1999;57(3):215–22.
55. Sun WH, Ou XL, Cao DZ, Yu Q, Yu T, Hu JM. Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. World J Gastroenterol. 2005;11(16):2477–81.
56. Chen CY, Lu CL, Luo JC, Chang FY, Lee SD, Lai YL. Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis. World J Gastroenterol. 2005;11(20):3112–7.
57. Ramachandran S, Shaheedha SM, Thirumurugan G, Dhanaraju MD. Floating controlled drug delivery system of famotidine loaded hollow microspheres (microballoons) in the stomach. Curr Drug Deliv. 2010;7(1):93–7.
58. Tokumura T, Machida Y. Preparation of amoxicillin intragastric buoyant sustained-release tablets and the dissolution characteristics. J Control Release. 2006;110(3):581–6.
59. Kumar Singh P, Pal Kaur I. Development and evaluation of a gastro-retentive delivery system for improved antiulcer activity of ginger extract (Zingiber officinale). J Drug Target. 2011;19(9):741–51.
60. Singh PK, Kaur IP. Synbiotic (probiotic and ginger extract) loaded floating beads: a novel therapeutic option in an experimental paradigm of gastric ulcer. J Pharm Pharmacol. 2012;64(2):207–17.
61. Vilaichone RK, Mahachai V, Tumwasorn S, Nunthapisud P, Kullavanijaya P. Inhibitory effect of Lactobacillus acidophilus on Helicobacter pylori in peptic ulcer patients: in vitro study. J Med Assoc Thai. 2002;85 Suppl 1:S79–84.
62. Parri MS, Gianetti J, Dushpanova A, Della Pina F, Saracini C, Marcucci R. Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial. Int J Cardiol. 2013;167(5):2177–81.
63. Sahasathian T, Praphairaksit N, Muangsin N. Mucoadhesive and floating chitosan-coated alginate beads for the controlled gastric release of amoxicillin. Arch Pharm Res. 2010;33(6):889–99.
64. Sriamornsak P. Development of calcium alginate floating beads prepared by ionotropic gelation technique. Thai J Pharm Sci. 2012;36:109.
65. Verma HC, Gupta RK. Anti-ulcer potential of ethyl cellulose floating microspheres containing ranitidine hydrochloride in experimental rodents. Asian J Pharm Clin Res. 2012;5:205–9.
66. Saravanan M, Anupama B. Development and evaluation of ethylcellulose floating microspheres loaded with ranitidine hydrochloride by novel solvent evaporation-matrix erosion method. Carbohyd Polym. 2011;85(3):592–8.
67. Goudanavar P, Reddy S, Hiremath D, Udupi R. Development and in vitro characterization of esomeprazole floating gastro retentive microspheres. J Appl Pharm Sci. 2013;3(3):071–7.
68. Singh V, Chaudhary AK. Preparation of Eudragit E100 microspheres by modified solvent evaporation method. Acta Pol Pharm. 2011;68(6):975–80.
69. Kumar PD, Lakshman L, Alekhya CV, Babu BV. Formulation and characterization of lansoprazole floating microspheres. Res J Pharm Dosage Forms Technol. 2012;4(2):128–32.
70. Samy AM, Ghorab MM, Shadeed SG, Mohamed NH. Design and optimization of ranitidine hydrochloride floating microspheres. Int J Pharm Pharm Sci. 2013;5(3):278–84.
71. Nagesh C, Venkatesh J, Santhosh Raj M, Rabadia J, Patil S, Shankraiah M. Intragastric floating drug delivery system of levofloxacin: formulation and evaluation. J Pharm Sci Res. 2011;3(6):1265–8.
72. Singh B, Pahuja S, Kapil R, Ahuja N. Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics. Acta Pharm. 2009;59(1):1–13.
73. Singh B, Chakkal SK, Ahuja N. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology. AAPS PharmSciTech. 2006;7(1):E3.
74. Shaikh R, Raj Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. J Pharm Bioallied Sci. 2011;3(1):89–100.
75. Boddupalli BM, Mohammed ZN, Nath RA, Banji D. Mucoadhesive drug delivery system: An overview. J Adv Pharm Technol Res. 2010;1(4):381–7.
76. Garg T, Rath G, Goyal AK. Novel technology to improve drug loading in polymeric nanofibers. Drug Deliv Lett. 2014;4(1):79–86.
77. Singh H, Sharma R, Joshi M, Garg T, Goyal AK, Rath G. Transmucosal delivery of docetaxel by mucoadhesive polymeric nanofibers. Artif Cells Nanomed Biotechnol. 2014. Epub ahead of print. Cited in PubMed; PMID 24621011.
78. Garg T, Arora S, Murthy R, Goyal AK. Development, optimization and evaluation of porous chitosan scaffold formulation of gliclazide for the treatment of type-2 diabetes mellitus. Drug Deliv Lett. 2012;2(4):251–61.
79. Garg T, Goyal AK. Liposomes: targeted and controlled delivery system. Drug Deliv Lett. 2014;4(1):62–71.
80. Gagandeep, Garg T, Malik B, Rath G, Goyal AK. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci. 2014;53:10–6.
81. Cuna M, Alonso MJ, Torres D. Preparation and in vivo evaluation of mucoadhesive microparticles containing amoxycillin-resin complexes for drug delivery to the gastric mucosa. Eur J Pharm Biopharm. 2001;51(3):199–205.
82. Liu Z, Lu W, Qian L, Zhang X, Zeng P, Pan J. In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. J Control Release. 2005;102(1):135–44.
83. Chun MK, Sah H, Choi HK. Preparation of mucoadhesive microspheres containing antimicrobial agents for eradication of H. pylori. Int J Pharm. 2005;297(1-2):172–9.
84. Nogueira F, Goncalves IC, Martins MC. Effect of gastric environment on Helicobacter pylori adhesion to a mucoadhesive polymer. Acta Biomater. 2013;9(2):5208–15.
85. Arora S, Budhiraja RD. Chitosan-alginate microcapsules of amoxicillin for gastric stability and mucoadhesion. J Adv Pharm Technol Res. 2012;3(1):68–74.
86. Liu YH, Zhu X, Zhou D, Jin Y, Zhao CY, Zhang ZR. pH-sensitive and mucoadhesive microspheres for duodenum-specific drug delivery system. Drug Dev Ind Pharm. 2011;37(7):868–74.
87. Zhu X, Zhou D, Guan S, Zhang P, Zhang Z, Huang Y. Preparation and characterization of novel multi-core chitosan microspheres for stomach-specific delivery of hydrophilic antibiotics. J Mater Sci Mater Med. 2012;23(4):983–90.
88. Sahasathian T, Praphairaksit N, Muangsin N. Mucoadhesive and floating chitosan-coated alginate beads for the controlled gastric release of amoxicillin. Arch Pharm Res. 2010;33(6):889–99.
89. Patel J, Patil P. Preparation and characterization of amoxicillin mucoadhesive microparticles using solution-enhanced dispersion by supercritical CO(2). J Microencapsul. 2012;29(4):398–408.
90. Patel JK, Chavda JR. Formulation and evaluation of stomach-specific amoxicillin-loaded carbopol- 934P mucoadhesive microspheres for anti-Helicobacter pylori therapy. J Microencapsul. 2009;26(4):365–76.
91. Srilakshmi N, Kumar DA, Pavani A, Reddy R. Preparation, characterization and evaluation of ranitidine mucoadhesive microspheres for prolonged gastric retention. Indo Am J Pharm Res. 2013;3(12):1269–80.
92. Sarparanta MP, Bimbo LM, Makila EM, Salonen JJ, Laaksonen PH, Helariutta AM. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. Biomaterials. 2012;33(11):3353–62.
93. Singh B, Rani A, Babita, Ahuja N, Kapil R. Formulation optimization of hydrodynamically balanced oral controlled release bioadhesive tablets of tramadol hydrochloride. Sci Pharm. 2010;78(2): 303–23.
94. Garg T, Bilandi A, Kapoor B. Scaffold: tissue engineering and regenerative medicine. Int Res J Pharm. 2011;2(12):37–42.
95. Garg T, Arora S. Opportunities and growth of conduct clinical trials in India. Int J Pharm Sci Rev Res. 2011;8(1):152–60.
96. Garg T, Singh S, Goyal AK. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst. 2013;30(5):369–409.
97. Arza RA, Gonugunta CS, Veerareddy PR. Formulation and evaluation of swellable and floating gastroretentive ciprofloxacin hydrochloride tablets. AAPS PharmSciTech. 2009;10(1):220–6.
98. Conway BR. Drug delivery strategies for the treatment of Helicobacter pylori infections. Curr Pharm Des. 2005;11(6):775–90.
99. Singh B, Sharma V. Design of psyllium-PVA-acrylic acid based novel hydrogels for use in antibiotic drug delivery. Int J Pharm. 2010;389(1-2):94–106.
100. Suedee R, Jantarat C, Lindner W, Viernstein H, Songkro S, Srichana T. Development of a pHresponsive drug delivery system for enantioselective-controlled delivery of racemic drugs. J Control Release. 2010;142(1):122–31.
101. Chavda HV, Patel CN. Preparation and in vitro evaluation of a stomach specific drug delivery system based on superporous hydrogel composite. Indian J Pharm Sci. 2011;73(1):30–7.
102. Figueiras A, Carvalho RA, Ribeiro L, Torres-Labandeira JJ, Veiga FJ. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin. Eur J Pharm Biopharm. 2007;67(2):531–9.
103. Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int J Pharm. 2006;316(1-2):86–92.
104. El-Zahaby SA, Kassem AA, El-Kamel AH. Formulation and in vitro evaluation of size expanding gastro-retentive systems of levofloxacin hemihydrate. Int J Pharm. 2014;464(1-2):10–8.
105. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 2012;29(1):1–63.
106. Chowdary K, Chaitanya C. Recent research on floating drug delivery systems—a review. J Global Trends Pharm Sci. 2014;5(1):1361–73.
107. Nayak KP, Upadhyay P, Valera JDAR, Chauhan NP. Gastroretentive drug delivery systems and recent approaches: a review. J Pharma Res Opinion. 2014;2(1):2–10.
108. Murphy CS, Pillay V, Choonara YE, du Toit LC. Gastroretentive drug delivery systems: current developments in novel system design and evaluation. Curr Drug Deliv. 2009;6(5):451–60.
109. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst. 1998;15(3):243–84.
110. Parnami N, Garg T, Rath G, Goyal AK. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol. 2013. Epub ahead of print. Cited in PubMed; PMID 24079701.
111. Dehvari K, Lin KS. Synthesis, characterization and potential applications of multifunctional PEOPPOPEO- magnetic drug delivery system. Curr Med Chem. 2012;19(30):5199–204.
112. Saravanan M, Balaji AB, Kavitha P, Kingsley JD. Controlled delivery of ranitidine in the stomach using magnetic field. West Indian Med J. 2009;58(2):87–91.
113. Prajapati VD, Jani GK, Khutliwala TA, Zala BS. Raft forming system—an upcoming approach of gastroretentive drug delivery system. J Control Release. 2013;168(2):151–65.
114. Hampson FC, Jolliffe IG, Bakhtyari A, Taylor G, Sykes J, Johnstone LM. Alginate-antacid combinations: raft formation and gastric retention studies. Drug Dev Indust Pharm. 2010;36(5):614–23.
115. Kwiatek MA, Roman S, Fareeduddin A, Pandolfino JE, Kahrilas PJ. An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patients. Aliment Pharm Therap. 2011;34(1):59–66.
116. Prajapati ST, Mehta AP, Modhia IP, Patel CN. Formulation and optimisation of raft-forming chewable tablets containing H2 antagonist. Int J Pharm Investig. 2012;2(4):176.
117. Rohof WO, Bennink RJ, Smout AJ, Thomas E, Boeckxstaens GE. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gastroent Hepatol. 2013;11(12):1585–91.
118. Prajapati VD, Jani GK, Khutliwala TA, Zala BS. Raft forming system—An upcoming approach of gastroretentive drug delivery system. J Control Release. 2013;168(2):151–65.
119. Washington N, Washington C, Wilson C, Davis S. The effect of inclusion of aluminium hydroxide in alginate-containing raft-forming antacids. Int J Pharm. 1986;28(2):139–43.
120. Key J, Aryal S, Gentile F, Ananta JS, Zhong M, Landis MD. Engineering discoidal polymeric nanoconstructs with enhanced magneto-optical properties for tumor imaging. Biomaterials. 2013;34(21):5402–10.